MarkMAwadMD

Clinical Fellow in Medicine, Brigham and Women's Hospital

Overview of Dr. Awad

Dr. Mark Awad is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, Brigham and Women's Hospital, and Dana-Farber Cancer Institute. He received his medical degree from Johns Hopkins University School of Medicine and has been in practice 9 years. He is one of 361 doctors at Brigham and Women's Hospital and one of 447 doctors at Dana-Farber Cancer Institute who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
530 East 74th Street
New York, NY 10021
Book by Phone+1(231) 508-8674

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2011 - 2014
Massachusetts General HospitalResidency, Internal Medicine, 2008 - 2011
Johns Hopkins University School of MedicineClass of 2008

Certifications & Licensure

FL State Medical License 2024 - Present
NY State Medical License 2024 - 2026
MA State Medical License 2012 - 2025
NJ State Medical License 2024 - 2025
NH State Medical License 2024 - 2024
RI State Medical License 2020 - 2020
American Board of Internal Medicine Medical Oncology

Clinical Trials

Merestinib In Non-Small Cell Lung Cancer And Solid Tumors Start of enrollment: 2016 Nov 11
Terminated
Phase 2
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma Start of enrollment: 2017 Apr 10
Suspended
Phase 2
A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer Start of enrollment: 2017 Jun 19
Terminated
Phase 1, Phase 2
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer Start of enrollment: 2019 Nov 05
ACTIVE_NOT_RECRUITING
PHASE3
Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer Start of enrollment: 2021 Nov 09
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Roles: Contact
Studying Pathways of Resistance in KRAS-driven Cancers Start of enrollment: 2022 Sep 08
Recruiting
Roles: Contact
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation Start of enrollment: 2023 Jul 12
RECRUITING
PHASE1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun
Nature. 2025-02-27
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) Pati...
Adriana P C Barrichello, Arielle Elkrief, Biagio Ricciuti, Teja Ganta, Thomas U Marron
Clinical Lung Cancer. 2025-02-04
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembr...
Alessio Cortellini, Leonardo Brunetti, Giuseppina Rita Di Fazio, Edoardo Garbo, David J Pinato
Journal for Immunotherapy of Cancer. 2025-02-04

Journal Articles

Authors’ Response
Matthew P Cheng, Mark M Awad, Journal of Thoracic Oncology

Lectures

Phase Ib study: Selective histone deacetylase (HDAC) inhibitor ACY-241 + nivolumab (Nivo) in advanced non-small cell lung cancer (NSCLC).
2019 ASCO Annual Meeting - 6/1/2019
Mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKIs) in MET exon 14 (METex14) mutant non-small cell lung cancer (NSCLC).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
ECHO-305/KEYNOTE-654: A phase 3, randomized, double-blind study of first-line epacadostat plus pembrolizumab vs pembrolizumab plus placebo for metastatic non small cel...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Authored Content

Authors’ ResponseOctober 2018

Press Mentions

Neoadjuvant Nivolumab plus Ipilimumab Shows Trend Towards Long-Term Clinical Benefit Versus Chemotherapy in Patients with Resectable NSCLCFebruary 24th, 2025
Questions to Ask if You've Been Diagnosed with Lung CancerNovember 1st, 2024
New Study to Address Cancer Treatment Resistance for People Who Are KRAS PositiveNovember 30th, 2022
Join now to see all